The DOI matches its Crossref record; 114 of the 114 references it cites were found in a registry or an index.
PROSTAGLANDINS AND CANCER
Open accessAbstract
Chemoprevention has been considered as a possible approach for cancer prevention. A significant effort has been made in the development of novel drugs for both cancer prevention and treatment over the past decade. Recent epidemiological studies and clinical trials indicate that long term use of aspirin and similar agents, also called non-steroidal anti-inflammatory drugs (NSAIDs), can decrease the incidence of certain malignancies, including colorectal, oesophageal, breast, lung, and bladder cancers. The best known targets of NSAIDs are cyclooxygenase (COX) enzymes, which convert arachidonic acid to prostaglandins (PGs) and thromboxane. COX-2 derived prostaglandin E(2)(PGE(2)) can promote tumour growth by binding its receptors and activating signalling pathways which control cell proliferation, migration, apoptosis, and/or angiogenesis. However, the prolonged use of high dosages of COX-2 selective inhibitors (COXIBs) is associated with unacceptable cardiovascular side effects. Thus it is crucial to develop more effective chemopreventive agents with minimal toxicity. Recent efforts to identify the molecular mechanisms by which PGE(2) promotes tumour growth and metastasis may provide opportunities for the development of safer strategies for cancer prevention and treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Inhibition of Prostaglandin Synthesis as a Mechanism of Action for Aspirin-like Drugs
VANE, J. R. (1971) · Nature New Biology · doi:10.1038/newbio231232a0 · Cited by 8,605
Inflammation and cancer: back to Virchow?
Balkwill, F., & Mantovani, A. (2001) · The Lancet · doi:10.1016/s0140-6736(00)04046-0 · Cited by 7,746
Bombardier, C., Laine, L., Reicin, A., Shapiro, D., Burgos-Vargas, R., Davis, B., Day, R., Ferraz, M. B., Hawkey, C. J., Hochberg, M. C., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200011233432103 · Cited by 4,027
Vane, J. R., Bakhle, Y. S., & Botting, R. M. (1998) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.38.1.97 · Cited by 2,734
The Effect of Celecoxib, a Cyclooxygenase-2 Inhibitor, in Familial Adenomatous Polyposis
Steinbach, G., Lynch, P. M., Phillips, R. K. S., Wallace, M. H., Hawk, E., Gordon, G. B., Wakabayashi, N., Saunders, B., Shen, Y., Fujimura, T., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200006293422603 · Cited by 2,526
Cardiovascular Events Associated with Rofecoxib in a Colorectal Adenoma Chemoprevention Trial
Bresalier, R. S., Sandler, R. S., Quan, H., Bolognese, J. A., Oxenius, B., Horgan, K., Lines, C., Riddell, R., Morton, D., Lanas, A., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050493 · Cited by 2,519
Cyclooxygenase in biology and disease
DuBois, R. N., Abramson, S. B., Crofford, L., Gupta, R. A., Simon, L. S., van de Putte, L. B. A., & Lipsky, P. E. (1998) · The FASEB Journal · doi:10.1096/fasebj.12.12.1063 · Cited by 2,506
Cancer and the chemokine network
Balkwill, F. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1388 · Cited by 2,343
Cyclooxygenase regulates angiogenesis induced by colon cancer cells
Tsujii, M., Kawano, S., Tsuji, S., Sawaoka, H., Hori, M., & DuBois, R. N. (1998) · Cell · doi:10.1016/s0092-8674(00)81433-6 · Cited by 2,272
Self-citationTsujii, M., & DuBois, R. N. (1995) · Cell · doi:10.1016/0092-8674(95)90127-2 · Cited by 2,267
Cited by
The lung microenvironment: an important regulator of tumour growth and metastasis
Altorki, N. K., Markowitz, G. J., Gao, D., Port, J. L., Saxena, A., Stiles, B., McGraw, T., & Mittal, V. (2019) · Nature Reviews Cancer · doi:10.1038/s41568-018-0081-9 · Cited by 1,150
Algra, A. M., & Rothwell, P. M. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70112-2 · Cited by 831
The role of COX‐2 in intestinal inflammation and colorectal cancer
Wang, D., & DuBois, R. N. (2010) · Oncogene · doi:10.1038/onc.2009.421 · Cited by 805
Self-citationEngineering CAR-T Cells for Next-Generation Cancer Therapy
Hong, M., Clubb, J. D., & Chen, Y. Y. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.07.005 · Cited by 639
Epidemiology of Glioblastoma Multiforme–Literature Review
Grochans, S., Cybulska, A. M., Simińska, D., Korbecki, J., Kojder, K., Chlubek, D., & Baranowska-Bosiacka, I. (2022) · Cancers · doi:10.3390/cancers14102412 · Cited by 630
Multifaceted roles of PGE2 in inflammation and cancer
Nakanishi, M., & Rosenberg, D. W. (2013) · Seminars in Immunopathology · doi:10.1007/s00281-012-0342-8 · Cited by 591
Prostanoids in health and disease
Smyth, E. M., Grosser, T., Wang, M., Yu, Y., & FitzGerald, G. A. (2009) · Journal of Lipid Research · doi:10.1194/jlr.r800094-jlr200 · Cited by 543
Overcoming cancer therapeutic bottleneck by drug repurposing
Zhang, Z., Zhou, L., Xie, N., Nice, E. C., Zhang, T., Cui, Y., & Huang, C. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00213-8 · Cited by 516
Signalling networks regulating cyclooxygenase-2
Tsatsanis, C., Androulidaki, A., Venihaki, M., & Margioris, A. N. (2006) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2006.03.021 · Cited by 492
Obermajer, N., Muthuswamy, R., Odunsi, K., Edwards, R. P., & Kalinski, P. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-2449 · Cited by 464
Anti-Inflammatory Drugs in the 21st Century
Rainsford, K. D. (2007) · Subcellular Biochemistry · doi:10.1007/1-4020-5688-5_1 · Cited by 463
Clinical Pharmacology of Non-Steroidal Anti-Inflammatory Drugs: A Review
Bacchi, S., Palumbo, P., Sponta, A., & Coppolino, M. F. (2012) · Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry · doi:10.2174/187152312803476255 · Cited by 433
Bosch, R., Philips, N., Suárez-Pérez, J., Juarranz, A., Devmurari, A., Chalensouk-Khaosaat, J., & González, S. (2015) · Antioxidants · doi:10.3390/antiox4020248 · Cited by 407
Properties of the Group IV phospholipase A2 family
GHOSH, M., TUCKER, D., BURCHETT, S., & LESLIE, C. (2006) · Progress in Lipid Research · doi:10.1016/j.plipres.2006.05.003 · Cited by 397
Anti-Inflammatory Drugs as Anticancer Agents
Zappavigna, S., Cossu, A. M., Grimaldi, A., Bocchetti, M., Ferraro, G. A., Nicoletti, G. F., Filosa, R., & Caraglia, M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21072605 · Cited by 395
Tafani, M., Sansone, L., Limana, F., Arcangeli, T., De Santis, E., Polese, M., Fini, M., & Russo, M. A. (2016) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2016/3907147 · Cited by 373
Cyclooxygenases, prostanoids, and tumor progression
Wang, M.-T., Honn, K. V., & Nie, D. (2007) · Cancer and Metastasis Reviews · doi:10.1007/s10555-007-9096-5 · Cited by 345
Anti-Inflammatory Agents for Cancer Therapy
Rayburn, E. (2009) · Molecular and Cellular Pharmacology · doi:10.4255/mcpharmacol.09.05 · Cited by 341
Extracellular matrix, inflammation, and the angiogenic response
Arroyo, A. G., & Iruela-Arispe, M. L. (2010) · Cardiovascular Research · doi:10.1093/cvr/cvq049 · Cited by 335
A Large Cohort Study of Long-Term Daily Use of Adult-Strength Aspirin and Cancer Incidence
Jacobs, E. J., Thun, M. J., Bain, E. B., Rodriguez, C., Henley, S. J., & Calle, E. E. (2007) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djk132 · Cited by 322
Platelets and cancer: a casual or causal relationship: revisited
Menter, D. G., Tucker, S. C., Kopetz, S., Sood, A. K., Crissman, J. D., & Honn, K. V. (2014) · Cancer and Metastasis Reviews · doi:10.1007/s10555-014-9498-0 · Cited by 316
NSAIDs and Cancer Prevention: Targets Downstream of COX-2
Cha, Y. I., & DuBois, R. N. (2007) · Annual Review of Medicine · doi:10.1146/annurev.med.57.121304.131253 · Cited by 308
Glutathione peroxidases in different stages of carcinogenesis
Brigelius-Flohé, R., & Kipp, A. (2009) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2009.03.006 · Cited by 305
Regulation of inflammation in cancer by eicosanoids
Greene, E. R., Huang, S., Serhan, C. N., & Panigrahy, D. (2011) · Prostaglandins & Other Lipid Mediators · doi:10.1016/j.prostaglandins.2011.08.004 · Cited by 303
Prostaglandin E2 and Cancer: Insight into Tumor Progression and Immunity
Finetti, F., Travelli, C., Ercoli, J., Colombo, G., Buoso, E., & Trabalzini, L. (2020) · Biology · doi:10.3390/biology9120434 · Cited by 302
Kaidi, A., Qualtrough, D., Williams, A. C., & Paraskeva, C. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-0425 · Cited by 300
Novel insights into G protein and G protein-coupled receptor signaling in cancer
O’Hayre, M., Degese, M. S., & Gutkind, J. S. (2014) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2014.01.005 · Cited by 296
Prostaglandin E2 Promotes Colorectal Cancer Stem Cell Expansion and Metastasis in Mice
Wang, D., Fu, L., Sun, H., Guo, L., & DuBois, R. N. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.07.064 · Cited by 292
Self-citationCytokines, Inflammation and Colon Cancer
Klampfer, L. (2011) · Current Cancer Drug Targets · doi:10.2174/156800911795538066 · Cited by 289
Oxidative Stress in the Tumor Microenvironment and Its Relevance to Cancer Immunotherapy
Aboelella, N. S., Brandle, C., Kim, T., Ding, Z.-C., & Zhou, G. (2021) · Cancers · doi:10.3390/cancers13050986 · Cited by 286
Aspirin, salicylates, and cancer
Elwood, P. C., Gallagher, A. M., Duthie, G. G., Mur, L. A., & Morgan, G. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60243-9 · Cited by 282
Phospholipase signalling networks in cancer
Park, J. B., Lee, C. S., Jang, J.-H., Ghim, J., Kim, Y.-J., You, S., Hwang, D., Suh, P.-G., & Ryu, S. H. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3379 · Cited by 276
Aspirin in the Chemoprevention of Colorectal Neoplasia: An Overview
Chan, A. T., Arber, N., Burn, J., Chia, W. K., Elwood, P., Hull, M. A., Logan, R. F., Rothwell, P. M., Schrör, K., & Baron, J. A. (2012) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-11-0391 · Cited by 276
Shaashua, L., Shabat-Simon, M., Haldar, R., Matzner, P., Zmora, O., Shabtai, M., Sharon, E., Allweis, T., Barshack, I., Hayman, L., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-0152 · Cited by 276
RNA-binding protein nucleolin in disease
Abdelmohsen, K., & Gorospe, M. (2012) · RNA Biology · doi:10.4161/rna.19718 · Cited by 272
The Role of Inflammation in Colon Cancer
Janakiram, N. B., & Rao, C. V. (2014) · Advances in Experimental Medicine and Biology · doi:10.1007/978-3-0348-0837-8_2 · Cited by 151
Low zinc status: a new risk factor for pneumonia in the elderly?
Barnett, J. B., Hamer, D. H., & Meydani, S. N. (2010) · Nutrition Reviews · doi:10.1111/j.1753-4887.2009.00253.x · Cited by 149
Reprogramming immunosuppressive myeloid cells facilitates immunotherapy for colorectal cancer
Lu, W., Yu, W., He, J., Liu, W., Yang, J., Lin, X., Zhang, Y., Wang, X., Jiang, W., Luo, J., et al. (2021) · EMBO Molecular Medicine · doi:10.15252/emmm.202012798 · Cited by 112
Targeting NF-κB and HIF-1 Pathways for the Treatment of Cancer: Part II
Wilczynski, J., Duechler, M., & Czyz, M. (2011) · Archivum Immunologiae et Therapiae Experimentalis · doi:10.1007/s00005-011-0132-3 · Cited by 41
Fordyce, C., Fessenden, T., Pickering, C., Jung, J., Singla, V., Berman, H., & Tlsty, T. (2010) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-09-0229 · Cited by 41
Metadata
- Authors
- Wang, D.
- Venue
- Gut
- Publisher
- BMJ
- Published
- 2006-01-01
- Volume
- 55
- Issue
- 1
- Pages
- 115-122
- ISSN
- 0017-5749 (ISSN-L)
- OpenAlex
- W2101249156
- Cited by
- 899
- References
- 114
- FWCI
- 28.11
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.